.jpeg)
Paradromics received FDA approval to recruit nationwide for its Connect-One feasibility study, removing the requirement to live within four hours of a clinical site. Eligible participants from across the US can now travel to one of the three US sites. A week before, the company announced a collaboration with Siemens Healthineers to develop an integrated imaging workflow for BCI patients, from surgical planning to implant placement.
Paradromics reported more than four years of stable neural recordings in two sheep implanted with electrodes representative of its Connexus BCI. Signal quality remained steady without electrode migration, while a separate six-sheep study of the full platform is approaching two years of stability. The findings support its long-term durability work as Paradromics advances its Connect-One human feasibility study for speech restoration.